Sequoia Capital China leads over $100m round in Bota Biosciences

Sequoia Capital China has led over $100 million Series B funding round in industrial synthetic biotech firm Bota Biosciences with the participation of new investor CMB International Capital, a Hong Kong-based subsidiary of China Merchants Bank.

The company has also roped in a host of returning investors such as Matrix Partners China, 5Y Capital, Source Code Capital, Sherpa Healthcare Partners, and Meituan, a Chinese conglomerate that runs one of the country’s biggest food delivery platforms called Dianping.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter